Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
SCNX Catalyst Timeline
Dated clinical, regulatory and corporate events for Scienture Holdings, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Scienture Holdings, Inc.
Upcoming catalysts 2
Event history 50
Past FDA Catalysts and PDUFA Decisions
How SCNX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-03-13 | Arbli (losartan potassium) | PDUFA Date Approved | PDUFA |
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every SCNX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Shankar HariharanDirector, Officer (Co-CEO & Chairman), 10% Owner | Acquisition | 500,000 3,518,679 held | $0.00 | 02/20/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in SCNX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in SCNX for Q2 2026. | ||||
Ownership Trends
SCNX Short Interest
Shares sold short, counted twice a month.
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How SCNX ranks across every disease it competes in
SCNX News
SCIENTURE Reports Q3 2026 Results with Approximately 265% Sequential Revenue Growth Driven by the Commercial Launch of REZENOPY™
Scienture Holdings reported a robust Q3 2026 with a 265% sequential revenue growth, reaching $1.25 million. The commercial launch of REZENOPY™ contributed significantly, generating approximately $925,000 in initial sales. Gross profit also saw a notable increase of 77.5% year-over-year. Despite these gains, the company reported a net loss of approximately $6.0 million for the quarter.
Read more →SCIENTURE Issues Shareholder Letter Highlighting Sequential Revenue Growth, Two FDA-Approved Commercial Products, and Continued Progress Toward Profitability in 2027
Scienture Holdings reported preliminary third-quarter 2026 revenue of $1.22 million, a 256% sequential increase. The growth followed the August commercial launch of REZENOPY™ and a 74% rise in Arbli™ wholesale unit sales. The company targets profitability in 2027 using its high gross margins and established commercial infrastructure.
Read more →SCIENTURE Reports Approximately $1.22 Million in Unaudited Preliminary Q3 2026 Revenue, Achieving 256% Sequential Growth
Scienture Holdings, Inc. reported preliminary Q3 2026 revenue of approximately $1.22 million, marking a 256% increase from the previous quarter. This growth is attributed to the successful launch of REZENOPY and increased sales of Arbli. The company aims to expand its pharmaceutical portfolio and achieve profitability by 2027.
Read more →SCIENTURE Announces Arbli™ Added to Formularies at Three Leading U.S. Pediatric Academic Medical Centers and Hospitals
Scienture Holdings, Inc. announced that its product Arbli™ has been added to the formularies of three prominent U.S. pediatric academic medical centers. This addition marks a significant milestone in expanding Arbli™'s market presence, particularly in pediatric care. The product, a proprietary oral suspension of losartan potassium, aims to improve patient access and compliance. Scienture anticipates continued growth driven by increasing wholesale orders and institutional adoption.
Read more →Scienture Holdings, Inc. Announces Reverse Stock Split
Scienture Holdings, Inc. announced a 1-for-25 reverse stock split effective October 5, 2026. This move aims to comply with Nasdaq's minimum bid price requirement and facilitate future share issuance. Post-split, the company will have approximately 1.64 million shares outstanding, with no change in par value or authorized shares.
Read more →SCIENTURE Expands Commercial Reach of REZENOPY™ to Addiction Treatment Centers through an Agreement with a Distribution Partner
Scienture Holdings, Inc. has announced an exclusive agreement to distribute REZENOPY™ through a partner network of approximately 2,000 opioid treatment clinics in the U.S. This partnership aims to enhance the availability of naloxone, a critical treatment for opioid overdoses. The agreement aligns with Scienture's broader commercialization strategy and is expected to significantly contribute to REZENOPY™'s revenue growth.
Read more →SCIENTURE to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026
Scienture Holdings, Inc. will present at the H.C. Wainwright 28th Annual Global Investment Conference from September 14-16, 2026. The company plans to showcase its commercial momentum, particularly the growing adoption of Arbli™ and the recent launch of REZENOPY™. Management anticipates significant revenue growth driven by these products and aims for profitability by 2027.
Read more →SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance
Scienture Holdings, Inc. reported significant financial improvements for Q2 2026, including a 510% increase in revenue compared to Q1 2026. The company's gross margin was approximately 97.7%, and both operating and net losses narrowed significantly year-over-year. The commercial launch of REZENOPY™ marks an expansion of their product portfolio, indicating a positive trajectory for future growth.
Read more →SCIENTURE Announces Commercial Launch and Fulfillment of Initial Purchase Orders of REZENOPY™, the Highest Dose FDA-Approved Naloxone Nasal Spray
Scienture Holdings, Inc. has announced the commercial launch of REZENOPY™, the highest-dose FDA-approved naloxone nasal spray. The product is designed for emergency treatment of opioid overdoses and has begun nationwide distribution following the fulfillment of initial purchase orders. Scienture aims to expand market access and adoption through a dedicated sales team and payer coverage.
Read more →SCIENTURE Announces Commercial Inventory Readiness and July Shipments of REZENOPY™ (naloxone hydrochloride) to Wholesalers
Scienture Holdings, Inc. announced the completion of manufacturing and upcoming shipments of REZENOPY™ (naloxone hydrochloride) Nasal Spray 10 mg to U.S. wholesalers, with commercial availability expected in August. This product is designed for emergency treatment of opioid overdoses and represents a significant opportunity in the $144 million naloxone market. The company has also expanded payer access to over 100 million lives, enhancing its market position.
Read more →SCIENTURE Expands Arbli™ Payor Coverage and Commercial Access, Adding Approximately 12.5 Million Covered Lives Nationwide
Scienture Holdings, Inc. has announced significant advancements in the commercialization of Arbli™, including expanded payor coverage that now includes approximately 12.5 million additional covered lives. The company is focusing on increasing patient access through broader pharmacy networks and channel partnerships. Arbli™, a liquid formulation of losartan, aims to improve compliance among patients who have difficulty swallowing tablets.
Read more →SCIENTURE Secures Formulary Coverage for REZENOPY™ with a Large National Health Plan and Expands Commercial Team
Scienture Holdings, Inc. announced that its naloxone product, REZENOPY™, has been added to the formulary of a large national health plan, enhancing access for over 100 million covered lives. The product, which is the highest FDA-approved naloxone dose available, is set for commercial launch in mid-July 2026. Scienture is also expanding its sales team to support the product's rollout across various healthcare sectors.
Read more →SCIENTURE Receives U.S. Patent Covering REZENOPY™ (Naloxone HCl) Nasal Spray 10 mg, Strengthening Intellectual Property Protection Through 2041
Scienture Holdings, Inc. announced the granting of U.S. Patent No. 12,622,903 B2 for REZENOPY™ (naloxone HCl) Nasal Spray 10 mg, effective May 12, 2026, expiring February 5, 2041. This patent strengthens their intellectual property and supports their exclusive commercialization rights in the U.S. The product, approved by the FDA, aims to address the opioid overdose crisis.
Read more →SCIENTURE Reports First Quarter 2026 Financial Results and Business Update Highlighted by Significant Revenue Growth and Gross Margin Expansion
Scienture Holdings, Inc. reported significant financial growth for Q1 2026, with revenue increasing by 449% year-over-year to approximately $56,000. The gross profit surged by 7900%, leading to a gross margin expansion to 95.6%. The company also secured key patents and financing to support its product portfolio and commercialization strategy. However, it reported a net loss of approximately $3.4 million.
Read more →Scienture Secures $11.0 Million in Non-Dilutive Debt Financing to Accelerate Growth of Approved Product Portfolio and Advancement of R&D Pipeline
Scienture Holdings has secured $11 million in non-dilutive debt financing to enhance its commercial efforts for its FDA-approved products, Arbli™ and REZENOPY™. The funds will also support the advancement of its R&D pipeline, which includes multiple therapeutic candidates. Company executives expressed confidence that this financing would help the company achieve profitability by 2027 and mentioned a focus on operational milestones. This strategic funding marks a significant step in the company's growth trajectory and commitment to patient care.
Read more →SCIENTURE Announces Third Patent Grant for ARBLI™ (losartan potassium) Oral Suspension, Strengthening Long-Term Market Exclusivity Through 2041
Scienture Holdings, Inc. announced the granting of a third patent for ARBLI™, its FDA-approved losartan potassium oral suspension. This patent, issued on April 21, 2026, extends intellectual property protection until October 2041. ARBLI™ offers a ready-to-use liquid formulation, enhancing patient compliance, particularly for those unable to swallow tablets. The product is positioned to capture significant market share in the $241 million U.S. losartan market.
Read more →Scienture Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
Scienture Holdings, Inc. has been granted a 180-day extension by Nasdaq to meet the minimum bid price requirement of $1.00 per share. The company has until October 12, 2026, to achieve compliance. Scienture highlights its potential for growth with the upcoming launch of Arbli™, a novel FDA-approved hypertension treatment, and REZENOPY™, a naloxone nasal spray. However, the company acknowledges challenges in maintaining Nasdaq compliance standards.
Read more →Scienture Provides Annual Shareholder Update, Outlining Significant Progress and Strategic Priorities for the Year Ahead
Scienture Holdings, Inc. provided a comprehensive annual update highlighting significant progress in its pharmaceutical platform. Key achievements include the successful launch of Arbli™, an FDA-approved liquid formulation of losartan, and the strategic acquisition of REZENOPY™, aimed at addressing opioid overdose. The company reported a 216% increase in net revenue year-over-year, despite a net loss due to a one-time impairment charge. Looking ahead, Scienture is focused on expanding its commercial portfolio and advancing its R&D pipeline.
Read more →SCIENTURE Reports Year End 2025 Financial Results and Provides Business Update
Scienture Holdings, Inc. reported a remarkable 216% increase in net revenue for the year ending December 31, 2025, reaching $431,609. The company also achieved a gross margin expansion to 76.8% and improved its operational efficiency. Key developments included the successful launch of Arbli™, which has gained significant traction in the market, and strategic collaborations to enhance access to its products. Despite a net loss attributed to a one-time impairment charge, the company is optimistic about its growth momentum into 2026.
Read more →SCIENTURE Broadens Commercial Access for REZENOPY™, Highest-Dose FDA-Approved Naloxone Nasal Spray, Through GPO Agreements Reaching Over 5,000 U.S. Institutions
Scienture Holdings, Inc. has announced the formalization of multiple Group Purchasing Organization (GPO) agreements for its FDA-approved naloxone nasal spray, REZENOPY™, increasing its access to over 5000 healthcare institutions in the U.S. This move is expected to enhance the product's adoption, leveraging the significant commercial opportunity presented by the naloxone market, which totals approximately $141 million annually. REZENOPY™ is positioned as the highest-dose naloxone formulation approved by the FDA and aims to address opioid overdose emergencies across various healthcare settings.
Read more →